Hormonal

Tirzepatide, a GLP-1/GIP dual receptor agonist, significantly reduces HbA1c levels (up to 2.24%) and body weight (up to 11.2 kg) in patients with type 2 diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine in head-to-head trials.

Tirzepatide is a once-weekly injection for Type 2 Diabetes and obesity that significantly lowers blood sugar and promotes weight loss, often more effectively than other common medications like semaglutide or insulin. It works by mimicking hormones that regulate insulin and appetite. Common side effects like nausea are usually manageable by starting with a low dose and eating smaller, low-fat meals. Due to high costs, check for insurance coverage or assistance programs.